

1094038

SEC 1972 (6-02) Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

ATTENTION
Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption state exemption unless such exemption is predicated on the filing of a federal notice.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
UNIFORM LIMITED OFFERING EXEMPTION

Table with OMB APPROVAL, OMB Number: 3235-0076, Expires: May 31, 2005, Estimated average burden hours per response.. . 1




Table with SEC USE ONLY, Prefix, Serial, DATE RECEIVED

PROCESSED
NOV 14 2002

Name of Offering (X) check if this is an amendment and name has changed, and indicate change.
GeneMax Corp. (formerly known as "Eduverse.com")

THOMSON FINANCIAL

Filing Under (Check box(es) that apply): [ ] Rule 504 [ ] Rule 505 [X] Rule 506 [ ] Section 4(6) [ ] ULOE

Type of Filing: [ ] New Filing [X] Amendment



02064764

A. BASIC IDENTIFICATION DATA

1. Enter the information requested about the issuer

Name of Issuer (X) check if this is an amendment and name has changed, and indicate change.)

GeneMax Corp. (formerly known as "Eduverse.com")

Address of Executive Offices (Number and Street, City, State, Zip Code) Telephone Number
(Including Area Code)

435 Martin St., Suite 2000, Blaine Washington 98230 (360) 332-7734

Address of Principal Business Operations (Number and Street, City, State, Zip Code) Telephone Number
(Including Area Code)
(if different from Executive Offices)

Not applicable

Brief Description of Business

See attachment A

Type of Business Organization

- [X] corporation [ ] limited partnership, already formed [ ] other (please specify):
[ ] business trust [ ] limited partnership, to be formed

Month Year

Actual or Estimated Date of Incorporation or Organization: [ 1 ] 0 [ 0 ] 1 [ x ] Actual [ ] Estimated  
 Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:  
 CN for Canada; FN for other foreign jurisdiction) [ N ] [ V ]

**GENERAL INSTRUCTIONS**

**Federal:**

*Who Must File:* All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C. 77d(6).

*When to File:* A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

*Where to File:* U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

*Copies Required:* Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of manually signed copy or bear typed or printed signatures.

*Information Required:* A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

*Filing Fee:* There is no federal filing fee.

**State:**

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix in the notice constitutes a part of this notice and must be completed.

**A. BASIC IDENTIFICATION DATA**

2. Enter the information requested for the following:

- Each promoter of the issuer, if the issuer has been organized within the past five years;
- Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer;
- Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and
- Each general and managing partner of partnership issuers.

Check Box(es) that Apply: [ ] Promoter [ x ] Beneficial Owner [ x ] Executive Officer [ x ] Director [ ] General and/or Managing Partner

Full Name (Last name first, if individual)

Handford, Ronald L.

Business or Residence Address (Number and Street, City, State, Zip Code)

3432 W. 13th Avenue, Vancouver, British Columbia V5Y 1W1

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Jefferies, Wilfred Dr.

Business or Residence Address (Number and Street, City, State, Zip Code)

12596 23rd Avenue, Surrey, British Columbia v4A 2C2

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Davidson, James D.

Business or Residence Address (Number and Street, City, State, Zip Code)

321 South St. Asaph Street, Alexandria VA 22314

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Levy, Julia Dr.

Business or Residence Address (Number and Street, City, State, Zip Code)

601 - 1490 Pennyfarthing Drive, Vancouver, British Columbia V6J 4Z3

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Lindsay, Alan P.

Business or Residence Address (Number and Street, City, State, Zip Code)

2701 Hornby Street, Vancouver, British Columbia V6Z 2R1

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Atkins, Grant R.

Business or Residence Address (Number and Street, City, State, Zip Code)

435 Martin Street, Suite 2000, Blaine WA 98230

Check Box(es) that Apply:  Promoter  Beneficial Owner  Executive Officer  Director  General and/or Managing Partner

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

**B. INFORMATION ABOUT OFFERING**

1. Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?..... Yes No [x] [ ]

Answer also in Appendix, Column 2, if filing under ULOE.

2. What is the minimum investment that will be accepted from any individual?..... \$ n/a

3. Does the offering permit joint ownership of a single unit?..... Yes No [x] [ ]

4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.

Full Name (Last name first, if individual)

Not applicable

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) ..... [ ] All States

- [AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID] [IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO] [MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) ..... [ ] All States

- [AL] [AK] [AZ] [AR] [CA] [CO] [CT] [DE] [DC] [FL] [GA] [HI] [ID] [IL] [IN] [IA] [KS] [KY] [LA] [ME] [MD] [MA] [MI] [MN] [MS] [MO] [MT] [NE] [NV] [NH] [NJ] [NM] [NY] [NC] [ND] [OH] [OK] [OR] [PA] [RI] [SC] [SD] [TN] [TX] [UT] [VT] [VA] [WA] [WV] [WI] [WY] [PR]

Full Name (Last name first, if individual)

Business or Residence Address (Number and Street, City, State, Zip Code)

Name of Associated Broker or Dealer

States in Which Person Listed Has Solicited or Intends to Solicit Purchasers

(Check "All States" or check individual States) ..... [ ] All States

[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[WA]	[WV]	[WI]	[WY]	[PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

**C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS**

1. Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.

Type of Security	Aggregate Offering Price	Amount Already Sold
Debt .....	\$ -0-	\$ -0-
Equity <u>share for share exchange</u> .....	\$ <u>2,204,231.50</u>	\$ <u>2,204,231.50</u>
<input checked="" type="checkbox"/> Common <input type="checkbox"/> Preferred		
Convertible Securities (including warrants) <u>share exchange</u> .....	\$ <u>588,745.00</u>	\$ <u>588,745.00</u>
Partnership Interests .....	\$ -0-	\$ -0-
Other (Specify _____) .....	\$ -0-	\$ -0-
Total .....	\$ <u>2,792,976.50</u>	\$ <u>2,792,976.50*</u>

Answer also in Appendix, Column 3, if filing under ULOE.

\*See attachment B

2. Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."

	Number Investors	Aggregate Dollar Amount of Purchases
Accredited Investors <u>/Regulation S investors</u> .....	<u>82</u>	\$ <u>n/a</u>
Non-accredited Investors .....	<u>3</u>	\$ <u>n/a</u>
Total (for filings under Rule 504 only) .....		\$

Answer also in Appendix, Column 4, if filing under ULOE.

3. If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C-Question 1.

Not applicable

Type of offering	Dollar Amount Sold
Rule 505 .....	\$
Regulation A .....	\$
Rule 504 .....	\$
Total .....	\$

4. a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.

Transfer Agent's Fees .....	<input type="checkbox"/>	\$ 2,700
Printing and Engraving Costs .....	<input type="checkbox"/>	\$ -0-
Legal Fees .....	<input type="checkbox"/>	\$ 70,300
Accounting Fees .....	<input type="checkbox"/>	\$ 20,000
Engineering Fees .....	<input type="checkbox"/>	\$ -0-
Sales Commissions (specify finders' fees separately) .....	<input type="checkbox"/>	\$ -0-
Other Expenses (identify) _____	<input type="checkbox"/>	\$ -0-
Total .....	<input type="checkbox"/>	\$ 93,000.00

b. Enter the difference between the aggregate offering price given in response to Part C - Question 1 and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer." ..... \$2,699,976.50


5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to be used for each of the purposes shown. If the amount for any purpose is not known, furnish an estimate and check the box to the left of the estimate. The total of the payments listed must equal the adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.

<b>Not applicable - see attachment B</b>		Payments to Officers,     Payments Directors, & To Affiliates     Others	
Salaries and fees .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Purchase of real estate .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Purchase, rental or leasing and installation of machinery and equipment .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Construction or leasing of plant buildings and facilities.....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Acquisition of other businesses (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger) .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Repayment of indebtedness .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Working capital .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Other (specify): _____	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
_____	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Column Totals .....	<input type="checkbox"/>	<input type="checkbox"/>	
	\$ _____	\$ _____	
Total Payments Listed (column totals added) .....	<input type="checkbox"/>	\$ _____	

**D. FEDERAL SIGNATURE**

The issuer has duly caused this notice to be signed by the undersigned duly authorized person. If this notice is filed under Rule 505, the following signature constitutes an undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon written request of its staff, the information furnished by the issuer

to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) GeneMax Corp.	Signature 	Date 10/18/02
Name of Signer (Print or Type) Ronald L. Handford, President/CEO	Title of Signer (Print or Type)	

<b>ATTENTION</b>
Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

**E. STATE SIGNATURE**

1. Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule? Yes No [ ] [x]

See Appendix, Column 5, for state response.

2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239,500) at such times as required by state law.

3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.

4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type) GeneMax Corp.	Signature	Date 10/18/02
Name of Signer (Print or Type) Ronald L. Handford	Title (Print or Type) President/CEO	

*Instruction:*

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed

to any non-accredited investor pursuant to paragraph (b)(2) of Rule 502.

Issuer (Print or Type) GeneMax Corp.	Signature	Date 10/18/02
Name of Signer (Print or Type) Ronald L. Handford, President/CEO	Title of Signer (Print or Type)	

<b>ATTENTION</b>
Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

**E. STATE SIGNATURE**

1. Is any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule? ..... [ ]


See Appendix, Column 5, for state response.

2. The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed, a notice on Form D (17 CFR 239,500) at such times as required by state law.

3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.

4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.

The issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

Issuer (Print or Type) GeneMax Corp.	Signature 	Date 10/18/02
Name of Signer (Print or Type) Ronald L. Handford	Title (Print or Type) President/CEO	

*Instruction:*

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed

**ATTACHMENT A TO FORM D  
FOR GENEMAX CORP.**

**A. BASIC IDENTIFICATION DATA**

**Brief Description of Business**

As of the date of this Form D, the Board of Directors of GeneMax Corp., a Nevada corporation and formerly known as "Eduverse.com" (the "Company"), has consummated and finalized the acquisition of GeneMax Pharmaceuticals Inc., a Delaware corporation ("GeneMax Pharmaceuticals"). On May 9, 2002, effective July 15, 2002, Eduverse.com (now known as GeneMax Corp.), the shareholders of GeneMax Pharmaceuticals (the "GeneMax Shareholders"), GeneMax Pharmaceuticals and Investor Communications International, Inc., a Washington corporation ("ICI") entered into a share exchange agreement (the "Share Exchange Agreement"). In accordance with the terms of the Share Exchange Agreement and the securities laws of Canada, a Directors' Circular dated July 15, 2002 (the "Directors' Circular") was distributed to certain management, insiders and directors of GeneMax Pharmaceuticals (the "Canadian GeneMax Shareholders").

Pursuant to the terms of the Share Exchange Agreement, effective July 15, 2002, the Company's name was changed to "GeneMax Corp." and its trading symbol under the OTC Bulletin Board for its shares of common stock was changed to "GMXX".

In accordance with the terms of the Share Exchange Agreement, the Company is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection.

**ATTACHMENT B TO FORM D  
FOR GENEMAX CORP.**

**C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE  
OF PROCEEDS**

Pursuant to the terms of the Share Exchange Agreement and the Directors' Circular, the Company has acquired from the GeneMax Shareholders and the Canadian GeneMax Shareholders up to approximately one hundred percent (100%) of the issued and outstanding shares of common stock of GeneMax Pharmaceuticals. In accordance with the terms of the Share Exchange Agreement, the Directors' Circular and related settlement agreements, the Company was required to issue shares of its restricted common stock as follows: (i) approximately 6,411,304 shares of restricted common stock to the GeneMax Shareholders in proportion to their respective holdings in GeneMax Pharmaceuticals; (ii) approximately 4,479,001 shares of restricted common stock to the Canadian GeneMax Shareholders pursuant to the terms of the Directors' Circular; (iii) 181,660 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$0.75 per share for settlement of an aggregate debt in the amount of \$136,245.00; (iv) 188,154 shares of restricted common stock to certain creditors of GeneMax Pharmaceuticals at \$1.00 per share for settlement of an aggregate debt in the amount of \$188,154.00; and (v) 200,000 shares of restricted common stock to a third party.

As of the date of this Form D, the Company has issued an aggregate of 11,460,119 shares of its restricted common stock. Certain shares were issued in accordance with the terms and provisions of warrant agreements pursuant to which the holder thereof has the right to convert such warrant into shares of common stock on a one-to-one basis at either the rate of \$0.75 per share or \$1.00 per share. As of the date of this Form D, there are an aggregate of (i) 277,500 warrants issued and outstanding which may be converted into 277,500 shares of common stock at the rate of \$1.00 per share expiring December 1, 2005; (ii) 175,000 warrants issued and outstanding which may be converted into 175,000 shares of common stock at the rate of \$1.00 per share expiring May 1, 2006; and (iii) 181,660 warrants issued and outstanding which may be converted into 181,660 shares of common stock at the rate of \$0.75 per share expiring May 1, 2006.

An aggregate offering price of \$2,792,976.50 was determined as follows. For purposes of valuation of the shares of common stock issued in accordance with the terms of the Share Exchange Agreement, an aggregate offering price of \$2,204,231.50 was determined as follows: (i) \$8,100.00 for 8,100,000 shares of common stock issued at \$0.001 per share; (ii) \$1,336,482.00 for 2,227,470 shares of common stock issued at \$0.60 per share; (iii) \$82,750.50 for 110,334 shares of common stock issued at \$0.75 per share; (iv) \$452,500.00 for 452,500 shares of common stock issued at \$1.00 per share; (v) \$136,245.00 for 181,660 shares of common stock issued at \$0.75 per share pursuant to debt settlement; and (vi) \$188,154.00 for 188,154 shares of common stock issued at \$1.00 per share pursuant to debt settlement. For purposes of valuation of the warrants issued, an aggregate offering price of \$588,745.00 was determined as follows: (i) \$136,245.00 for 181,660 warrants exercisable into 181,660 shares of common stock at \$0.75 per share; and (ii) \$452,500.00 for 452,500 warrants exercisable into 452,500 shares of common stock at \$1.00 per share.